Spero TherapeuticsSPRO +1.19%55 Earnings Yield (Joel Greenblatt) % is 17.33% as of Mar. 2026. GuruFocus rates SPRO with a GF Score™ of 55/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,339 Biotechnology companies, Spero Therapeutics ranks better than 97.09% on this metric.
Spero Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $81.81 Mil.
Spero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $14.18 Mil. Spero Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 17.33%.
The historical rank and industry rank for Spero Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
SPRO'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6961.45 Med: -30.87 Max: 14826.1
Current: 20.53
During the past 11 years, the highest Earnings Yield (Joel Greenblatt) of Spero Therapeutics was 14826.10%. The lowest was -6961.45%. And the median was -30.87%.
SPRO's Earnings Yield (Joel Greenblatt) % is ranked better than 97.09% of 1339
companies
in the Biotechnology industry
Industry Median: -9.84
vs SPRO: 20.53
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Spero Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Spero Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms
Spero Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Spero Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spero Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Spero Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Spero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.18 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 17.33% mean?
Spero Therapeutics (SPRO) has a Earnings Yield (Joel Greenblatt) % of 17.33% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Spero Therapeutics and its competitors. According to the industry distribution chart, Spero Therapeutics ranks #39 out of 1339 companies in the Biotechnology industry, placing it in the top 2.9%.
Is Spero Therapeutics' Earnings Yield (Joel Greenblatt) % too high?
Spero Therapeutics' current Earnings Yield (Joel Greenblatt) % is 17.33%. Based on the distribution chart, Spero Therapeutics ranks #39 out of 1339 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Earnings Yield (Joel Greenblatt) % compare to VXRT and ADCT?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #39 out of 1339 companies for Earnings Yield (Joel Greenblatt) %. This places Spero Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Spero Therapeutics and its competitors. Spero Therapeutics's current Earnings Yield (Joel Greenblatt) % is 17.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $2.12 — trading 101.9% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 17.33%. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Earnings Yield (Joel Greenblatt) % is 17.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of $2.12 is trading 101.9% above its estimated GF Value™ of $1.05.
GuruFocus considers Spero Therapeutics to be Significantly Overvalued.
Key valuation signals for SPRO:
Earnings Yield (Joel Greenblatt) %: 17.33%
GF Value™: $1.05 vs. price of $2.12 (101.9% above fair value)
No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
55GF Score
Get the complete analysis for SPRO
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRO has been successfully added to your 
